ACTA PHARM SIN B 润色咨询

Acta Pharmaceutica Sinica B

出版年份：暂无数据 年文章数：894 投稿命中率： 开通期刊会员，数据随心看

出版周期：暂无数据 自引率：3.5% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2292798, encodeId=e0732292e984f, content=10.31 submit<br>11.27 under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5a5548378, createdName=药不药, createdTime=Thu Dec 11 10:17:28 CST 2025, time=2025-12-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2288552, encodeId=a5fa228855250, content=Under Review要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2e99824760, createdName=ms9000000929280541, createdTime=Tue Nov 11 22:16:34 CST 2025, time=2025-11-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2286790, encodeId=6b5e2286e9043, content=还没有<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f279811886, createdName=ms8000001203006034, createdTime=Wed Oct 29 21:23:38 CST 2025, time=2025-10-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2243080, encodeId=3029224308039, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤学<br>经验分享：请问需要流式的原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ece5698328, createdName=ms2000001785238562, createdTime=Tue Dec 17 10:34:35 CST 2024, time=2024-12-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2212910, encodeId=824c2212910f4, content=审稿速度:2.0<br>偏重的研究方向：肿瘤<br>经验分享：自从收到预接受文件满心欢喜。修回格式已经20天了，还没有收到正式接收的邮件，心里忐忑不安。。。。有没有朋友遇到同样情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=ed509121182, createdName=科研~菜鸟, createdTime=Wed Jul 03 08:54:51 CST 2024, time=2024-07-03, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2239955, encodeId=634c22399558e, content=这个杂志不建议投，真慢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faf92276694, createdName=121b8024m37(暂无昵称), createdTime=Fri Nov 29 19:54:09 CST 2024, time=2024-11-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254019, encodeId=29e3225401951, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：24.5 投稿，24.6大修，24.7再修，24.10接收，21.12见刊<br>药学顶刊，审稿人和编辑要求都非常严谨，虽然速度较慢，但是非常开心被接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06645707969, createdName=ms8000000053730142, createdTime=Fri Feb 28 14:46:22 CST 2025, time=2025-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2149724, encodeId=9c952149e2440, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：生物;药理<br>经验分享：2月12日投稿，6月13日正式接收。正式接受后一个多月都没有出proof版本，请问一般这个杂志出proof要多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e7d2228833, createdName=Mr.Curiosity, createdTime=Tue Jul 25 11:41:51 CST 2023, time=2023-07-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2237949, encodeId=d77a223e94955, content=偏重的研究方向：肿瘤<br>经验分享：请问下，投稿之后需要所有作者确认吗 ？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d539038449, createdName=ms8000000170261507, createdTime=Wed Nov 20 11:08:46 CST 2024, time=2024-11-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2094226, encodeId=6a6e20942265e, content=为什么他们Decision in Process也很长时间啊！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Mon Oct 17 15:06:43 CST 2022, time=2022-10-17, status=1, ipAttribution=)]
    2025-12-11 药不药 来自北京

    10.31 submit
    11.27 under review

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2292798, encodeId=e0732292e984f, content=10.31 submit<br>11.27 under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5a5548378, createdName=药不药, createdTime=Thu Dec 11 10:17:28 CST 2025, time=2025-12-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2288552, encodeId=a5fa228855250, content=Under Review要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2e99824760, createdName=ms9000000929280541, createdTime=Tue Nov 11 22:16:34 CST 2025, time=2025-11-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2286790, encodeId=6b5e2286e9043, content=还没有<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f279811886, createdName=ms8000001203006034, createdTime=Wed Oct 29 21:23:38 CST 2025, time=2025-10-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2243080, encodeId=3029224308039, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤学<br>经验分享：请问需要流式的原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ece5698328, createdName=ms2000001785238562, createdTime=Tue Dec 17 10:34:35 CST 2024, time=2024-12-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2212910, encodeId=824c2212910f4, content=审稿速度:2.0<br>偏重的研究方向：肿瘤<br>经验分享：自从收到预接受文件满心欢喜。修回格式已经20天了，还没有收到正式接收的邮件，心里忐忑不安。。。。有没有朋友遇到同样情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=ed509121182, createdName=科研~菜鸟, createdTime=Wed Jul 03 08:54:51 CST 2024, time=2024-07-03, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2239955, encodeId=634c22399558e, content=这个杂志不建议投，真慢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faf92276694, createdName=121b8024m37(暂无昵称), createdTime=Fri Nov 29 19:54:09 CST 2024, time=2024-11-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254019, encodeId=29e3225401951, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：24.5 投稿，24.6大修，24.7再修，24.10接收，21.12见刊<br>药学顶刊，审稿人和编辑要求都非常严谨，虽然速度较慢，但是非常开心被接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06645707969, createdName=ms8000000053730142, createdTime=Fri Feb 28 14:46:22 CST 2025, time=2025-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2149724, encodeId=9c952149e2440, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：生物;药理<br>经验分享：2月12日投稿，6月13日正式接收。正式接受后一个多月都没有出proof版本，请问一般这个杂志出proof要多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e7d2228833, createdName=Mr.Curiosity, createdTime=Tue Jul 25 11:41:51 CST 2023, time=2023-07-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2237949, encodeId=d77a223e94955, content=偏重的研究方向：肿瘤<br>经验分享：请问下，投稿之后需要所有作者确认吗 ？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d539038449, createdName=ms8000000170261507, createdTime=Wed Nov 20 11:08:46 CST 2024, time=2024-11-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2094226, encodeId=6a6e20942265e, content=为什么他们Decision in Process也很长时间啊！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Mon Oct 17 15:06:43 CST 2022, time=2022-10-17, status=1, ipAttribution=)]
    2025-11-11 ms9000000929280541 来自北京

    Under Review要多久啊

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2292798, encodeId=e0732292e984f, content=10.31 submit<br>11.27 under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5a5548378, createdName=药不药, createdTime=Thu Dec 11 10:17:28 CST 2025, time=2025-12-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2288552, encodeId=a5fa228855250, content=Under Review要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2e99824760, createdName=ms9000000929280541, createdTime=Tue Nov 11 22:16:34 CST 2025, time=2025-11-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2286790, encodeId=6b5e2286e9043, content=还没有<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f279811886, createdName=ms8000001203006034, createdTime=Wed Oct 29 21:23:38 CST 2025, time=2025-10-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2243080, encodeId=3029224308039, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤学<br>经验分享：请问需要流式的原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ece5698328, createdName=ms2000001785238562, createdTime=Tue Dec 17 10:34:35 CST 2024, time=2024-12-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2212910, encodeId=824c2212910f4, content=审稿速度:2.0<br>偏重的研究方向：肿瘤<br>经验分享：自从收到预接受文件满心欢喜。修回格式已经20天了，还没有收到正式接收的邮件，心里忐忑不安。。。。有没有朋友遇到同样情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=ed509121182, createdName=科研~菜鸟, createdTime=Wed Jul 03 08:54:51 CST 2024, time=2024-07-03, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2239955, encodeId=634c22399558e, content=这个杂志不建议投，真慢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faf92276694, createdName=121b8024m37(暂无昵称), createdTime=Fri Nov 29 19:54:09 CST 2024, time=2024-11-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254019, encodeId=29e3225401951, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：24.5 投稿，24.6大修，24.7再修，24.10接收，21.12见刊<br>药学顶刊，审稿人和编辑要求都非常严谨，虽然速度较慢，但是非常开心被接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06645707969, createdName=ms8000000053730142, createdTime=Fri Feb 28 14:46:22 CST 2025, time=2025-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2149724, encodeId=9c952149e2440, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：生物;药理<br>经验分享：2月12日投稿，6月13日正式接收。正式接受后一个多月都没有出proof版本，请问一般这个杂志出proof要多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e7d2228833, createdName=Mr.Curiosity, createdTime=Tue Jul 25 11:41:51 CST 2023, time=2023-07-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2237949, encodeId=d77a223e94955, content=偏重的研究方向：肿瘤<br>经验分享：请问下，投稿之后需要所有作者确认吗 ？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d539038449, createdName=ms8000000170261507, createdTime=Wed Nov 20 11:08:46 CST 2024, time=2024-11-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2094226, encodeId=6a6e20942265e, content=为什么他们Decision in Process也很长时间啊！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Mon Oct 17 15:06:43 CST 2022, time=2022-10-17, status=1, ipAttribution=)]
    2025-10-29 ms8000001203006034 来自广东省

    还没有

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2292798, encodeId=e0732292e984f, content=10.31 submit<br>11.27 under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5a5548378, createdName=药不药, createdTime=Thu Dec 11 10:17:28 CST 2025, time=2025-12-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2288552, encodeId=a5fa228855250, content=Under Review要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2e99824760, createdName=ms9000000929280541, createdTime=Tue Nov 11 22:16:34 CST 2025, time=2025-11-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2286790, encodeId=6b5e2286e9043, content=还没有<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f279811886, createdName=ms8000001203006034, createdTime=Wed Oct 29 21:23:38 CST 2025, time=2025-10-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2243080, encodeId=3029224308039, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤学<br>经验分享：请问需要流式的原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ece5698328, createdName=ms2000001785238562, createdTime=Tue Dec 17 10:34:35 CST 2024, time=2024-12-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2212910, encodeId=824c2212910f4, content=审稿速度:2.0<br>偏重的研究方向：肿瘤<br>经验分享：自从收到预接受文件满心欢喜。修回格式已经20天了，还没有收到正式接收的邮件，心里忐忑不安。。。。有没有朋友遇到同样情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=ed509121182, createdName=科研~菜鸟, createdTime=Wed Jul 03 08:54:51 CST 2024, time=2024-07-03, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2239955, encodeId=634c22399558e, content=这个杂志不建议投，真慢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faf92276694, createdName=121b8024m37(暂无昵称), createdTime=Fri Nov 29 19:54:09 CST 2024, time=2024-11-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254019, encodeId=29e3225401951, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：24.5 投稿，24.6大修，24.7再修，24.10接收，21.12见刊<br>药学顶刊，审稿人和编辑要求都非常严谨，虽然速度较慢，但是非常开心被接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06645707969, createdName=ms8000000053730142, createdTime=Fri Feb 28 14:46:22 CST 2025, time=2025-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2149724, encodeId=9c952149e2440, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：生物;药理<br>经验分享：2月12日投稿，6月13日正式接收。正式接受后一个多月都没有出proof版本，请问一般这个杂志出proof要多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e7d2228833, createdName=Mr.Curiosity, createdTime=Tue Jul 25 11:41:51 CST 2023, time=2023-07-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2237949, encodeId=d77a223e94955, content=偏重的研究方向：肿瘤<br>经验分享：请问下，投稿之后需要所有作者确认吗 ？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d539038449, createdName=ms8000000170261507, createdTime=Wed Nov 20 11:08:46 CST 2024, time=2024-11-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2094226, encodeId=6a6e20942265e, content=为什么他们Decision in Process也很长时间啊！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Mon Oct 17 15:06:43 CST 2022, time=2022-10-17, status=1, ipAttribution=)]
    2024-12-17 ms2000001785238562 来自吉林省

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向：肿瘤学
    经验分享：请问需要流式的原始数据吗？

    3

    展开3条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2292798, encodeId=e0732292e984f, content=10.31 submit<br>11.27 under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5a5548378, createdName=药不药, createdTime=Thu Dec 11 10:17:28 CST 2025, time=2025-12-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2288552, encodeId=a5fa228855250, content=Under Review要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2e99824760, createdName=ms9000000929280541, createdTime=Tue Nov 11 22:16:34 CST 2025, time=2025-11-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2286790, encodeId=6b5e2286e9043, content=还没有<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f279811886, createdName=ms8000001203006034, createdTime=Wed Oct 29 21:23:38 CST 2025, time=2025-10-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2243080, encodeId=3029224308039, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤学<br>经验分享：请问需要流式的原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ece5698328, createdName=ms2000001785238562, createdTime=Tue Dec 17 10:34:35 CST 2024, time=2024-12-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2212910, encodeId=824c2212910f4, content=审稿速度:2.0<br>偏重的研究方向：肿瘤<br>经验分享：自从收到预接受文件满心欢喜。修回格式已经20天了，还没有收到正式接收的邮件，心里忐忑不安。。。。有没有朋友遇到同样情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=ed509121182, createdName=科研~菜鸟, createdTime=Wed Jul 03 08:54:51 CST 2024, time=2024-07-03, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2239955, encodeId=634c22399558e, content=这个杂志不建议投，真慢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faf92276694, createdName=121b8024m37(暂无昵称), createdTime=Fri Nov 29 19:54:09 CST 2024, time=2024-11-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254019, encodeId=29e3225401951, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：24.5 投稿，24.6大修，24.7再修，24.10接收，21.12见刊<br>药学顶刊，审稿人和编辑要求都非常严谨，虽然速度较慢，但是非常开心被接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06645707969, createdName=ms8000000053730142, createdTime=Fri Feb 28 14:46:22 CST 2025, time=2025-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2149724, encodeId=9c952149e2440, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：生物;药理<br>经验分享：2月12日投稿，6月13日正式接收。正式接受后一个多月都没有出proof版本，请问一般这个杂志出proof要多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e7d2228833, createdName=Mr.Curiosity, createdTime=Tue Jul 25 11:41:51 CST 2023, time=2023-07-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2237949, encodeId=d77a223e94955, content=偏重的研究方向：肿瘤<br>经验分享：请问下，投稿之后需要所有作者确认吗 ？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d539038449, createdName=ms8000000170261507, createdTime=Wed Nov 20 11:08:46 CST 2024, time=2024-11-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2094226, encodeId=6a6e20942265e, content=为什么他们Decision in Process也很长时间啊！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Mon Oct 17 15:06:43 CST 2022, time=2022-10-17, status=1, ipAttribution=)]
    2024-07-03 科研~菜鸟 来自河南省

    审稿速度:2.0
    偏重的研究方向：肿瘤
    经验分享：自从收到预接受文件满心欢喜。修回格式已经20天了，还没有收到正式接收的邮件，心里忐忑不安。。。。有没有朋友遇到同样情况的？

    8

    展开8条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2292798, encodeId=e0732292e984f, content=10.31 submit<br>11.27 under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5a5548378, createdName=药不药, createdTime=Thu Dec 11 10:17:28 CST 2025, time=2025-12-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2288552, encodeId=a5fa228855250, content=Under Review要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2e99824760, createdName=ms9000000929280541, createdTime=Tue Nov 11 22:16:34 CST 2025, time=2025-11-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2286790, encodeId=6b5e2286e9043, content=还没有<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f279811886, createdName=ms8000001203006034, createdTime=Wed Oct 29 21:23:38 CST 2025, time=2025-10-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2243080, encodeId=3029224308039, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤学<br>经验分享：请问需要流式的原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ece5698328, createdName=ms2000001785238562, createdTime=Tue Dec 17 10:34:35 CST 2024, time=2024-12-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2212910, encodeId=824c2212910f4, content=审稿速度:2.0<br>偏重的研究方向：肿瘤<br>经验分享：自从收到预接受文件满心欢喜。修回格式已经20天了，还没有收到正式接收的邮件，心里忐忑不安。。。。有没有朋友遇到同样情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=ed509121182, createdName=科研~菜鸟, createdTime=Wed Jul 03 08:54:51 CST 2024, time=2024-07-03, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2239955, encodeId=634c22399558e, content=这个杂志不建议投，真慢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faf92276694, createdName=121b8024m37(暂无昵称), createdTime=Fri Nov 29 19:54:09 CST 2024, time=2024-11-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254019, encodeId=29e3225401951, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：24.5 投稿，24.6大修，24.7再修，24.10接收，21.12见刊<br>药学顶刊，审稿人和编辑要求都非常严谨，虽然速度较慢，但是非常开心被接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06645707969, createdName=ms8000000053730142, createdTime=Fri Feb 28 14:46:22 CST 2025, time=2025-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2149724, encodeId=9c952149e2440, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：生物;药理<br>经验分享：2月12日投稿，6月13日正式接收。正式接受后一个多月都没有出proof版本，请问一般这个杂志出proof要多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e7d2228833, createdName=Mr.Curiosity, createdTime=Tue Jul 25 11:41:51 CST 2023, time=2023-07-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2237949, encodeId=d77a223e94955, content=偏重的研究方向：肿瘤<br>经验分享：请问下，投稿之后需要所有作者确认吗 ？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d539038449, createdName=ms8000000170261507, createdTime=Wed Nov 20 11:08:46 CST 2024, time=2024-11-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2094226, encodeId=6a6e20942265e, content=为什么他们Decision in Process也很长时间啊！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Mon Oct 17 15:06:43 CST 2022, time=2022-10-17, status=1, ipAttribution=)]
    2024-11-29 121b8024m37(暂无昵称) 来自河南省

    这个杂志不建议投，真慢！

    4

    展开4条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2292798, encodeId=e0732292e984f, content=10.31 submit<br>11.27 under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5a5548378, createdName=药不药, createdTime=Thu Dec 11 10:17:28 CST 2025, time=2025-12-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2288552, encodeId=a5fa228855250, content=Under Review要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2e99824760, createdName=ms9000000929280541, createdTime=Tue Nov 11 22:16:34 CST 2025, time=2025-11-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2286790, encodeId=6b5e2286e9043, content=还没有<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f279811886, createdName=ms8000001203006034, createdTime=Wed Oct 29 21:23:38 CST 2025, time=2025-10-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2243080, encodeId=3029224308039, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤学<br>经验分享：请问需要流式的原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ece5698328, createdName=ms2000001785238562, createdTime=Tue Dec 17 10:34:35 CST 2024, time=2024-12-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2212910, encodeId=824c2212910f4, content=审稿速度:2.0<br>偏重的研究方向：肿瘤<br>经验分享：自从收到预接受文件满心欢喜。修回格式已经20天了，还没有收到正式接收的邮件，心里忐忑不安。。。。有没有朋友遇到同样情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=ed509121182, createdName=科研~菜鸟, createdTime=Wed Jul 03 08:54:51 CST 2024, time=2024-07-03, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2239955, encodeId=634c22399558e, content=这个杂志不建议投，真慢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faf92276694, createdName=121b8024m37(暂无昵称), createdTime=Fri Nov 29 19:54:09 CST 2024, time=2024-11-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254019, encodeId=29e3225401951, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：24.5 投稿，24.6大修，24.7再修，24.10接收，21.12见刊<br>药学顶刊，审稿人和编辑要求都非常严谨，虽然速度较慢，但是非常开心被接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06645707969, createdName=ms8000000053730142, createdTime=Fri Feb 28 14:46:22 CST 2025, time=2025-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2149724, encodeId=9c952149e2440, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：生物;药理<br>经验分享：2月12日投稿，6月13日正式接收。正式接受后一个多月都没有出proof版本，请问一般这个杂志出proof要多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e7d2228833, createdName=Mr.Curiosity, createdTime=Tue Jul 25 11:41:51 CST 2023, time=2023-07-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2237949, encodeId=d77a223e94955, content=偏重的研究方向：肿瘤<br>经验分享：请问下，投稿之后需要所有作者确认吗 ？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d539038449, createdName=ms8000000170261507, createdTime=Wed Nov 20 11:08:46 CST 2024, time=2024-11-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2094226, encodeId=6a6e20942265e, content=为什么他们Decision in Process也很长时间啊！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Mon Oct 17 15:06:43 CST 2022, time=2022-10-17, status=1, ipAttribution=)]
    2025-02-28 ms8000000053730142 来自江苏省

    审稿速度:1.0 | 投稿命中率:25.0
    经验分享：24.5 投稿，24.6大修，24.7再修，24.10接收，21.12见刊
    药学顶刊，审稿人和编辑要求都非常严谨，虽然速度较慢，但是非常开心被接收！

    2

    展开2条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2292798, encodeId=e0732292e984f, content=10.31 submit<br>11.27 under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5a5548378, createdName=药不药, createdTime=Thu Dec 11 10:17:28 CST 2025, time=2025-12-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2288552, encodeId=a5fa228855250, content=Under Review要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2e99824760, createdName=ms9000000929280541, createdTime=Tue Nov 11 22:16:34 CST 2025, time=2025-11-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2286790, encodeId=6b5e2286e9043, content=还没有<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f279811886, createdName=ms8000001203006034, createdTime=Wed Oct 29 21:23:38 CST 2025, time=2025-10-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2243080, encodeId=3029224308039, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤学<br>经验分享：请问需要流式的原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ece5698328, createdName=ms2000001785238562, createdTime=Tue Dec 17 10:34:35 CST 2024, time=2024-12-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2212910, encodeId=824c2212910f4, content=审稿速度:2.0<br>偏重的研究方向：肿瘤<br>经验分享：自从收到预接受文件满心欢喜。修回格式已经20天了，还没有收到正式接收的邮件，心里忐忑不安。。。。有没有朋友遇到同样情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=ed509121182, createdName=科研~菜鸟, createdTime=Wed Jul 03 08:54:51 CST 2024, time=2024-07-03, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2239955, encodeId=634c22399558e, content=这个杂志不建议投，真慢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faf92276694, createdName=121b8024m37(暂无昵称), createdTime=Fri Nov 29 19:54:09 CST 2024, time=2024-11-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254019, encodeId=29e3225401951, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：24.5 投稿，24.6大修，24.7再修，24.10接收，21.12见刊<br>药学顶刊，审稿人和编辑要求都非常严谨，虽然速度较慢，但是非常开心被接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06645707969, createdName=ms8000000053730142, createdTime=Fri Feb 28 14:46:22 CST 2025, time=2025-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2149724, encodeId=9c952149e2440, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：生物;药理<br>经验分享：2月12日投稿，6月13日正式接收。正式接受后一个多月都没有出proof版本，请问一般这个杂志出proof要多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e7d2228833, createdName=Mr.Curiosity, createdTime=Tue Jul 25 11:41:51 CST 2023, time=2023-07-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2237949, encodeId=d77a223e94955, content=偏重的研究方向：肿瘤<br>经验分享：请问下，投稿之后需要所有作者确认吗 ？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d539038449, createdName=ms8000000170261507, createdTime=Wed Nov 20 11:08:46 CST 2024, time=2024-11-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2094226, encodeId=6a6e20942265e, content=为什么他们Decision in Process也很长时间啊！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Mon Oct 17 15:06:43 CST 2022, time=2022-10-17, status=1, ipAttribution=)]
    2023-07-25 Mr.Curiosity 来自安徽省

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向：生物;药理
    经验分享：2月12日投稿，6月13日正式接收。正式接受后一个多月都没有出proof版本，请问一般这个杂志出proof要多久

    6

    展开6条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2292798, encodeId=e0732292e984f, content=10.31 submit<br>11.27 under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5a5548378, createdName=药不药, createdTime=Thu Dec 11 10:17:28 CST 2025, time=2025-12-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2288552, encodeId=a5fa228855250, content=Under Review要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2e99824760, createdName=ms9000000929280541, createdTime=Tue Nov 11 22:16:34 CST 2025, time=2025-11-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2286790, encodeId=6b5e2286e9043, content=还没有<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f279811886, createdName=ms8000001203006034, createdTime=Wed Oct 29 21:23:38 CST 2025, time=2025-10-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2243080, encodeId=3029224308039, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤学<br>经验分享：请问需要流式的原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ece5698328, createdName=ms2000001785238562, createdTime=Tue Dec 17 10:34:35 CST 2024, time=2024-12-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2212910, encodeId=824c2212910f4, content=审稿速度:2.0<br>偏重的研究方向：肿瘤<br>经验分享：自从收到预接受文件满心欢喜。修回格式已经20天了，还没有收到正式接收的邮件，心里忐忑不安。。。。有没有朋友遇到同样情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=ed509121182, createdName=科研~菜鸟, createdTime=Wed Jul 03 08:54:51 CST 2024, time=2024-07-03, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2239955, encodeId=634c22399558e, content=这个杂志不建议投，真慢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faf92276694, createdName=121b8024m37(暂无昵称), createdTime=Fri Nov 29 19:54:09 CST 2024, time=2024-11-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254019, encodeId=29e3225401951, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：24.5 投稿，24.6大修，24.7再修，24.10接收，21.12见刊<br>药学顶刊，审稿人和编辑要求都非常严谨，虽然速度较慢，但是非常开心被接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06645707969, createdName=ms8000000053730142, createdTime=Fri Feb 28 14:46:22 CST 2025, time=2025-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2149724, encodeId=9c952149e2440, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：生物;药理<br>经验分享：2月12日投稿，6月13日正式接收。正式接受后一个多月都没有出proof版本，请问一般这个杂志出proof要多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e7d2228833, createdName=Mr.Curiosity, createdTime=Tue Jul 25 11:41:51 CST 2023, time=2023-07-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2237949, encodeId=d77a223e94955, content=偏重的研究方向：肿瘤<br>经验分享：请问下，投稿之后需要所有作者确认吗 ？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d539038449, createdName=ms8000000170261507, createdTime=Wed Nov 20 11:08:46 CST 2024, time=2024-11-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2094226, encodeId=6a6e20942265e, content=为什么他们Decision in Process也很长时间啊！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Mon Oct 17 15:06:43 CST 2022, time=2022-10-17, status=1, ipAttribution=)]
    2024-11-20 ms8000000170261507 来自湖北省

    偏重的研究方向：肿瘤
    经验分享：请问下，投稿之后需要所有作者确认吗 ？

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2292798, encodeId=e0732292e984f, content=10.31 submit<br>11.27 under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5a5548378, createdName=药不药, createdTime=Thu Dec 11 10:17:28 CST 2025, time=2025-12-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2288552, encodeId=a5fa228855250, content=Under Review要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2e99824760, createdName=ms9000000929280541, createdTime=Tue Nov 11 22:16:34 CST 2025, time=2025-11-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2286790, encodeId=6b5e2286e9043, content=还没有<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f279811886, createdName=ms8000001203006034, createdTime=Wed Oct 29 21:23:38 CST 2025, time=2025-10-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2243080, encodeId=3029224308039, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤学<br>经验分享：请问需要流式的原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ece5698328, createdName=ms2000001785238562, createdTime=Tue Dec 17 10:34:35 CST 2024, time=2024-12-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2212910, encodeId=824c2212910f4, content=审稿速度:2.0<br>偏重的研究方向：肿瘤<br>经验分享：自从收到预接受文件满心欢喜。修回格式已经20天了，还没有收到正式接收的邮件，心里忐忑不安。。。。有没有朋友遇到同样情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=ed509121182, createdName=科研~菜鸟, createdTime=Wed Jul 03 08:54:51 CST 2024, time=2024-07-03, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2239955, encodeId=634c22399558e, content=这个杂志不建议投，真慢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faf92276694, createdName=121b8024m37(暂无昵称), createdTime=Fri Nov 29 19:54:09 CST 2024, time=2024-11-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254019, encodeId=29e3225401951, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：24.5 投稿，24.6大修，24.7再修，24.10接收，21.12见刊<br>药学顶刊，审稿人和编辑要求都非常严谨，虽然速度较慢，但是非常开心被接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06645707969, createdName=ms8000000053730142, createdTime=Fri Feb 28 14:46:22 CST 2025, time=2025-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2149724, encodeId=9c952149e2440, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：生物;药理<br>经验分享：2月12日投稿，6月13日正式接收。正式接受后一个多月都没有出proof版本，请问一般这个杂志出proof要多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e7d2228833, createdName=Mr.Curiosity, createdTime=Tue Jul 25 11:41:51 CST 2023, time=2023-07-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2237949, encodeId=d77a223e94955, content=偏重的研究方向：肿瘤<br>经验分享：请问下，投稿之后需要所有作者确认吗 ？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d539038449, createdName=ms8000000170261507, createdTime=Wed Nov 20 11:08:46 CST 2024, time=2024-11-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2094226, encodeId=6a6e20942265e, content=为什么他们Decision in Process也很长时间啊！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Mon Oct 17 15:06:43 CST 2022, time=2022-10-17, status=1, ipAttribution=)]
    2022-10-17 ms9000000615443695

    为什么他们Decision in Process也很长时间啊！！！

    6

    展开6条回复
共194条页码: 1/20页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分